SHIVA GUPTA to Protein Kinase Inhibitors
This is a "connection" page, showing publications SHIVA GUPTA has written about Protein Kinase Inhibitors.
Connection Strength
0.176
-
In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Mol Cancer Ther. 2021 06; 20(6):1009-1018.
Score: 0.063
-
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther. 2017 11; 363(2):136-147.
Score: 0.049
-
Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells. Biochem Biophys Res Commun. 2017 04 29; 486(2):307-313.
Score: 0.047
-
Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. J Pharmacol Exp Ther. 2022 10; 383(1):91-102.
Score: 0.017